Evidence map›Paper›PMID 40280558›Full record

ArticleJournal of medicinal chemistry2025

Discovery of Novel, Potent, and Orally Bioavailable SMARCA2 Proteolysis-Targeting Chimeras with Synergistic Antitumor Activity in Combination with Kirsten Rat Sarcoma Viral Oncogene Homologue G12C Inhibitors.

Sasikumar Kotagiri, Yawen Wang, Yanyan Han, Xiaobing Liang, Nicholas Blazanin, Hira Mazhar, Manu Sebastian, Phuong Kieu Nguyen, Yongying Jiang, Yonathan Lissanu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Sasikumar KotagiriDepartment of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United states.
Yawen WangDepartment of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United states.
Yanyan HanDepartment of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United states.
Xiaobing LiangDepartment of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United states.
Nicholas BlazaninDepartment of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United states.
Hira MazharDepartment of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United states.
Manu SebastianDeptartment of Veterinary Medicine & Surgery and Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United states.
Phuong Kieu NguyenInstitute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, United states.
Yongying JiangInstitute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, United states.
Yonathan LissanuDepartment of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United states.ORCID 0000-0003-1024-5303

Funding

Mechanisms and Vulnerabilities of SWI/SNF chromatin remodeling complex mutant lung cancerR37CA251629 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LISSANU, YONATHAN · 2020 to 2025
$3.3M
Targeting SMARCA2 as a therapeutic strategy in SMARCA4 mutant lung cancerR01CA272945 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Yonathan Lissanu · 2022 to 2026
$2.7M
NCI NIH HHS R01 CA272945NCI NIH HHS R37 CA251629
6 · The paper itself

Abstract

Cancer genomic studies have identified frequent mutations in subunits of the SWI/SNF chromatin remodeling complex, including

Indexed as

Antineoplastic AgentsDNA HelicasesNuclear ProteinsProto-Oncogene Proteins p21(ras)Transcription FactorsAdministration, OralAnimalsCell Line, TumorCell ProliferationDrug DiscoveryDrug SynergismFemaleHumansLung NeoplasmsMiceMice, NudeAntineoplastic AgentsDNA HelicasesKRAS protein, humanNuclear ProteinsPiperazinesProto-Oncogene Proteins p21(ras)PyridazinesSMARCA2 protein, humanSMARCA4 protein, humanTranscription Factors

Identifiers

PMID40280558
PMCPMC12067438

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.